Praxis Precision Medicines, Inc. (PRAX)
PRAX Stock Price Chart
Explore Praxis Precision Medicines, Inc. interactive price chart. Choose custom timeframes to analyze PRAX price movements and trends.
PRAX Company Profile
Discover essential business fundamentals and corporate details for Praxis Precision Medicines, Inc. (PRAX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Oct 2020
Employees
116.00
Website
https://www.praxismedicines.comCEO
Marcio Silva De'Souza
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
PRAX Financial Timeline
Browse a chronological timeline of Praxis Precision Medicines, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Apr 2026
Upcoming earnings on 26 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$3.45.
Earnings released on 4 Aug 2025
EPS came in at -$3.31 surpassing the estimated -$3.40 by +2.65%.
Earnings released on 2 May 2025
EPS came in at -$3.29 falling short of the estimated -$3.20 by -2.81%.
Earnings released on 28 Feb 2025
EPS came in at -$2.94 falling short of the estimated -$2.76 by -6.52%, while revenue for the quarter reached $7.46M , beating expectations by +2.41K%.
Earnings released on 6 Nov 2024
EPS came in at -$2.75 falling short of the estimated -$2.01 by -36.82%, while revenue for the quarter reached $302.00K , missing expectations by -17.26%.
Earnings released on 13 Aug 2024
EPS came in at -$1.74 surpassing the estimated -$2.38 by +26.89%, while revenue for the quarter reached $357.00K , missing expectations by -56.99%.
Earnings released on 13 May 2024
EPS came in at -$2.84 falling short of the estimated -$2.01 by -41.29%, while revenue for the quarter reached $431.00K , missing expectations by -73.40%.
Earnings released on 5 Mar 2024
EPS came in at -$2.97 surpassing the estimated -$3.15 by +5.71%, while revenue for the quarter reached $515.00K , beating expectations by +930.00%.
Stock split effective on 29 Nov 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Nov 2023
EPS came in at -$2.70 surpassing the estimated -$5.25 by +48.57%, while revenue for the quarter reached $468.00K .
Earnings released on 9 Aug 2023
EPS came in at -$7.35 surpassing the estimated -$9.90 by +25.76%, while revenue for the quarter reached $781.00K .
Earnings released on 11 May 2023
EPS came in at -$10.64 surpassing the estimated -$11.24 by +5.34%, while revenue for the quarter reached $683.00K .
Earnings released on 7 Feb 2023
EPS came in at -$13.04 falling short of the estimated -$10.94 by -19.20%.
Earnings released on 9 Nov 2022
EPS came in at -$14.39 falling short of the estimated -$13.79 by -4.35%.
Earnings released on 8 Aug 2022
EPS came in at -$19.79 falling short of the estimated -$19.49 by -1.54%.
Earnings released on 9 May 2022
EPS came in at -$22.64 falling short of the estimated -$19.34 by -17.06%.
Earnings released on 28 Feb 2022
EPS came in at -$19.49 falling short of the estimated -$16.19 by -20.38%.
Earnings released on 3 Nov 2021
EPS came in at -$14.99 falling short of the estimated -$13.94 by -7.53%.
Earnings released on 16 Aug 2021
EPS came in at -$13.19 falling short of the estimated -$10.19 by -29.44%.
Earnings released on 11 May 2021
EPS came in at -$10.64 surpassing the estimated -$11.09 by +4.06%.
Earnings released on 17 Mar 2021
EPS came in at -$13.04 falling short of the estimated -$5.70 by -128.77%.
Earnings released on 23 Nov 2020
EPS came in at -$12.10 falling short of the estimated -$0.73 by -1.56K%.
Earnings released on 16 Oct 2020
EPS came in at -$105.64 .
PRAX Stock Performance
Access detailed PRAX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.